Targeting cancers with chromosome instability

Alex Eccleston

DOI: https://doi.org/10.1038/d41573-022-00111-4

IF: 112.288

2022-07-02

Nature Reviews Drug Discovery

Abstract:Nature Reviews Drug Discovery, Published online: 01 July 2022; doi:10.1038/d41573-022-00111-4 Targeting cancers with chromosome instability

pharmacology & pharmacy,biotechnology & applied microbiology

What problem does this paper attempt to address?

Targeting chromosomal instability and aneuploidy in cancer

Sugandha Bhatia,Kum Kum Khanna,Pascal H G Duijf,Pascal H.G. Duijf

DOI: https://doi.org/10.1016/j.tips.2024.01.009

IF: 17.638

2024-03-08

Trends in Pharmacological Sciences

Abstract:Cancer development and therapy resistance are driven by chromosomal instability (CIN), which causes chromosome gains and losses (i.e., aneuploidy) and structural chromosomal alterations. Technical limitations and knowledge gaps have delayed therapeutic targeting of CIN and aneuploidy in cancers. However, our toolbox for creating and studying aneuploidy in cell models has greatly expanded recently. Moreover, accumulating evidence suggests that seven conventional antimitotic chemotherapeutic drugs achieve clinical response by inducing CIN instead of mitotic arrest, although additional anticancer activities may also contribute in vivo. In this review, we discuss these recent developments. We also highlight new discoveries, which together show that 25 chromosome arm aneuploidies (CAAs) may be targetable by 36 drugs across 14 types of cancer. Collectively, these advances offer many new opportunities to improve cancer treatment.

pharmacology & pharmacy
A CINful way to overcome addiction: how chromosomal instability enables cancer to overcome its oncogene addiction

Daniel Bronder,Samuel F Bakhoum

DOI: https://doi.org/10.15252/emmm.202012017

2020-03-06

Abstract:Oncogene-addicted tumors present a valuable target for therapeutic intervention and an opportunity to achieve a wide therapeutic window. Nonetheless, resistance to targeted therapies is frequently observed and it arises through multiple mechanisms, including mutations in the target gene. Chromosomal instability, a defining feature of human cancer, has been linked to targeted therapy resistance, but the mechanism underlying this association is poorly understood. In the current issue of EMBO Molecular Medicine, Salgueiro et al show that chromosomal instability can lead to the generation of alternative oncogenic drivers, thereby providing the ability for cancer cells to overcome the oncogene withdrawal bottleneck. Importantly, this study shows that, by generating de novo genomic diversity, chromosomal instability serves as an adaptive response to therapeutic insult.
Abstract IA15: Single cell origins and targeting of genomic instability in breast cancers

Samuel Aparicio

DOI: https://doi.org/10.1158/1538-7445.advbc23-ia15

IF: 11.2

2024-02-02

Cancer Research

Abstract:Early whole genome sequencing studies have emphasised the different modes by which breast cancers can evolve. However, bulk NGS tissue analysis obscures mutations that are contemporaneous and/or lead to negative selection, and does not resolve clone specific metrics such as replication rate and fitness. We have developed single cell genome sequencing methods (Laks et al., Cell 2019) to identify large scale copy number-structural (CNA-SV) mutational processes that result in genomic shuffling through the duplication or deletion of chromosomal regions, obscured by bulk tissue analysis. This has revealed the existence and activity of distinct "foreground" mutational processes, i.e. mutational events in single mitoses that are observed directly, before the effects of purifying selection. We discovered that foreground processes are preferentially associated with background patterns of genome instability (Funnell et al., Nature 2022). We also discovered that CNA-SV mutational patterns are associated with relative sensitivity or resistance to platinum, a commonly used DNA targeting agent in TNBC and HGSOC. Our second recent discovery has been the association of CNA-SV mutations with clonal resistance to platinum in TNBC (Salehi et al., Nature 2021). Taken together, we now understand that ongoing CNA-SV mutations contribute to the evolution of fitness landscapes for DNA targeting therapeutics. In parallel work (Xu et al Nat. comms 2017) we have discovered stabilisers of folded DNA guanine stacked bases, G-quadruplexes (G4), to be synthetically lethal in contexts including HR and TMEJ that are underpinned by the single cell processes identified through single genome sequencing. To this end we have recently observed G4-ligand clinical activity in BRCA2 and PALB2 mutated cancers in a phase 1 trial (Hilton et al, Nature communication 2022). Citation Format: Samuel Aparicio. Single cell origins and targeting of genomic instability in breast cancers [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Breast Cancer Research; 2023 Oct 19-22; San Diego, California. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_1) nr IA15.

oncology
Targeting RNA and Protein Turnover in Aneuploid Cancers

Samuel F. Bakhoum

DOI: https://doi.org/10.1158/2159-8290.cd-24-1350

IF: 28.2

2024-12-04

Cancer Discovery

Abstract:Summary: Aneuploidy, an imbalance in chromosome number, is a hallmark of human cancers with chromosomal instability, and it remains a major therapeutic challenge. In this issue, Ippolito and colleagues identify RNA and protein turnover as targetable therapeutic vulnerabilities in aneuploid cancers. See related article by Ippolito et al., p. 2532

oncology
Abstract IA010: Latest developments in targeting the DNA damage response in the clinic

Timothy A. Yap

DOI: https://doi.org/10.1158/1538-7445.ovarian23-ia010

IF: 11.2

2024-03-04

Cancer Research

Abstract:Abstract Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA damage response (DDR) and/or increased replication stress. These alterations promote the clonal evolution of cancer cells via the accumulation of driver aberrations, including gene copy-number changes, rearrangements, and mutations; however, these same defects also create vulnerabilities that are relatively specific to cancer cells, which could potentially be exploited to increase the therapeutic index of anticancer treatments and thereby improve patient outcomes. The discovery that BRCA-mutant cancer cells are exquisitely sensitive to inhibition of poly(ADP-ribose) polymerase has ushered in a new era of research on biomarker-driven synthetic lethal treatment strategies for different cancers. The therapeutic landscape of antitumor agents targeting the DDR has rapidly expanded to include inhibitors of other key mediators of DNA repair and replication, such as ATM, ATR, CHK1 and CHK2, DNA-PK, POLQ, USP1 and WEE1. Efforts to optimize these therapies are ongoing across a range of cancers, involving the development of predictive biomarker assays of responsiveness (beyond BRCA mutations), assessment of the mechanisms underlying intrinsic and acquired resistance, and evaluation of rational, tolerable combinations with standard-of-care treatments (such as chemotherapeutics and radiation), novel molecularly targeted agents and immune-checkpoint inhibitors. Citation Format: Timothy A. Yap. Latest developments in targeting the DNA damage response in the clinic [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2):Abstract nr IA010.

oncology
Decoding the genetic program of micronucleus formation: linking chromosomal instability to human disease

Jörg Fahrer

DOI: https://doi.org/10.1038/s41392-024-01869-2

IF: 39.3

2024-06-14

Signal Transduction and Targeted Therapy

Abstract:Signal Transduction and Targeted Therapy, Published online: 14 June 2024; doi:10.1038/s41392-024-01869-2 Decoding the genetic program of micronucleus formation: linking chromosomal instability to human disease

biochemistry & molecular biology,cell biology
The Role of Non-Coding RNAs in Chromosomal Instability in Cancer

Swati Mohapatra,Melanie Winkle,Anh N Ton,Dien Nguyen,George A Calin

DOI: https://doi.org/10.1124/jpet.122.001357

Abstract:Chromosomal instability (CIN) is characterized by an increased frequency of changes in chromosome structure or number and is regarded as a hallmark of cancer. CIN plays a prevalent role in tumorigenesis and cancer progression by assisting the cancer cells' phenotypic adaptation to stress, which have been tightly linked to therapy resistance and metastasis. Both CIN-inducing and CIN-repressing agents are being clinically tested for the treatment of cancer to increase CIN levels to unsustainable levels leading to cell death or to decrease CIN levels to limit the development of drug resistance, respectively. Non-coding RNAs (ncRNAs) including microRNAs and long ncRNAs (lncRNAs) have been fundamentally implicated in CIN. The miR-22, miR-26a, miR-28, and miR-186 target important checkpoint proteins involved in mediating chromosomal stability and their expression modulation has been directly related to CIN occurrence. lncRNAs derived from telomeric, centrosomal, and enhancer regions play an important role in mediating genome stability, while specific lncRNA transcripts including genomic instability inducing RNA called Ginir, P53-responsive lncRNA termed as GUARDIN, colon cancer-associated transcript 2, PCAT2, and ncRNA activated by DNA damage called NORAD have been shown to act within CIN-associated pathways. In this review, we discuss how these ncRNAs either maintain or disrupt the stability of chromosomes and how these mechanisms could be exploited for novel therapeutic approaches targeting CIN in cancer patients. SIGNIFICANCE STATEMENT: Chromosomal instability increases tumor heterogeneity and thereby assists the phenotypic adaptation of cancer cells, causing therapy resistance and metastasis. Several microRNAs and long non-coding RNAs that have been causally linked to chromosomal instability could represent novel therapeutic targets. Understanding the role of non-coding RNAs in regulating different genes involved in driving chromosomal instability will give insights into how non-coding RNAs can be utilized toward modifying chemotherapeutic regimens in different cancers.
Abstract MS1-3: Targeting DNA damage response and HRD in breast cancer

TA Yap

DOI: https://doi.org/10.1158/1538-7445.sabcs21-ms1-3

IF: 11.2

2022-02-15

Cancer Research

Abstract:Abstract Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA damage response (DDR) and/or increased replication stress. These alterations promote the clonal evolution of cancer cells via the accumulation of driver aberrations, including gene copy-number changes, rearrangements and mutations; however, these same defects also create vulnerabilities that are relatively specific to cancer cells, which could potentially be exploited to increase the therapeutic index of anticancer treatments and thereby improve patient outcomes. The discovery that BRCA-mutant cancer cells are exquisitely sensitive to inhibition of poly(ADP-ribose) polymerase has ushered in a new era of research on biomarker-driven synthetic lethal treatment strategies for breast and other cancers. The therapeutic landscape of antitumor agents targeting the DDR has rapidly expanded to include inhibitors of other key mediators of DNA repair and replication, such as ATR, WEE1, ATM, PK-MYT1, DNA-PK, POLQ and USP1. Efforts to optimize these therapies are ongoing across a range of cancers, involving the development of predictive biomarker assays of responsiveness (beyond BRCA mutations), assessment of the mechanisms underlying intrinsic and acquired resistance, and evaluation of rational, tolerable combinations with standard-of-care treatments, novel molecularly targeted agents and immune-checkpoint inhibitors. Citation Format: TA Yap. Targeting DNA damage response and HRD in breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr MS1-3.

oncology
Therapeutic index of targeting select chromatin complexes in human cancer patients

Yuan Gao,Christopher R Vakoc

DOI: https://doi.org/10.1016/j.gde.2024.102162

IF: 4.665

2024-04-01

Current Opinion in Genetics & Development

Abstract:Aberrant chromatin regulation can promote the initiation and progression of human cancer. An improved understanding of such mechanisms has resulted in the identification of cancers with an enhanced dependency on specific chromatin regulatory proteins relative to nonmalignant cell types. Hence, targeting of such complexes with small molecules has significant therapeutic potential in oncology. In recent years, several drugs have been developed and evaluated in human cancer patients, which can influence tumor biology by reprogramming of chromatin structure. In this review, we summarize several of the known mechanisms that endow cancer cells with a powerful dependency on chromatin regulation that exceeds the requirements for normal tissue homeostasis. We also summarize the remarkable small-molecule inhibitors that exploit chromatin regulator dependencies with a clear therapeutic benefit in human cancer patients.

cell biology,genetics & heredity
Chromosomal instability as a driver of cancer progression

Xuelan Chen,Albert S Agustinus,Jun Li,Melody DiBona,Samuel F Bakhoum

DOI: https://doi.org/10.1038/s41576-024-00761-7

2024-07-29

Abstract:Chromosomal instability (CIN) refers to an increased propensity of cells to acquire structural and numerical chromosomal abnormalities during cell division, which contributes to tumour genetic heterogeneity. CIN has long been recognized as a hallmark of cancer, and evidence over the past decade has strongly linked CIN to tumour evolution, metastasis, immune evasion and treatment resistance. Until recently, the mechanisms by which CIN propels cancer progression have remained elusive. Beyond the generation of genomic copy number heterogeneity, recent work has unveiled additional tumour-promoting consequences of abnormal chromosome segregation. These mechanisms include complex chromosomal rearrangements, epigenetic reprogramming and the induction of cancer cell-intrinsic inflammation, emphasizing the multifaceted role of CIN in cancer.
Chromosome instability functions as a potential therapeutic reference by enhancing chemosensitivity to BCL-XL inhibitors in colorectal carcinoma

Xiao Fang,Wen-ying Yu,Chun-miao Zhu,Nan Zhao,Wei Zhao,Ting-ting Xie,Li-jie Wei,Xi-ran Sun,Juan Xie,Ya Zhao

DOI: https://doi.org/10.1038/s41401-024-01372-y

IF: 7.169

2024-08-27

Acta Pharmacologica Sinica

Abstract:Chromosome instability (CIN) and subsequent aneuploidy are prevalent in various human malignancies, influencing tumor progression such as metastases and relapses. Extensive studies demonstrate the development of chemoresistance in high-CIN tumors, which poses significant therapeutic challenges. Given the association of CIN with poorer prognosis and suppressed immune microenvironment observed in colorectal carcinoma (CRC), here we aimed to discover chemotherapeutic drugs exhibiting increased inhibition against high-CIN CRC cells. By using machine learning methods, we screened out two BCL-XL inhibitors Navitoclax and WEHI-539 as CIN-sensitive reagents in CRC. Subsequent analyses using a CIN-aneuploidy cell model confirmed the vulnerability of high-CIN CRC cells to these drugs. We further revealed the critical role of BCL-XL in the viability of high-CIN CRC cells. In addition, to ease the evaluation of CIN levels in clinic, we developed a three-gene signature as a CIN surrogate to predict prognosis, chemotherapeutic and immune responses in CRC samples. Our results demonstrate the potential value of CIN as a therapeutic target in CRC treatment and the importance of BCL-XL in regulating survival of high-CIN CRC cells, therefore representing a valuable attempt to translate a common trait of heterogeneous tumor cells into an effective therapeutic target.

pharmacology & pharmacy,chemistry, multidisciplinary
Abstract 4293: Chromosomal instability causes epigenetic aberrations in cancer

Albert S. Agustinus,Duaa Al-Rawi,Bhargavi Dameracharla,Ramya Raviram,Bailey S. Jones,Stephanie Stransky,Lorenzo Scipioni,Jens Luebeck,Melody Di Bona,Danguole Norkunaite,Robert M. Myers,Mercedes Duran,Seongmin Choi,Britta Weigelt,Shira Yomtoubian,Andrew McPherson,Eleonore Toufektchan,Kristina Keuper,Paul S. Mischel,Vivek Mittal,Sohrab P. Shah,John Maciejowski,Zuzana Storchova,Enrico Gratton,Peter Ly,Dan Landau,Mathieu F. Bakhoum,Richard P. Koche,Simone Sidoli,Vineet Bafna,Yael David,Samuel F. Bakhoum

DOI: https://doi.org/10.1158/1538-7445.am2024-4293

IF: 11.2

2024-03-24

Cancer Research

Abstract:Chromosomal instability and changes in the epigenome are defining features in most metastatic cancers. Our research links chromosomal missegregation, their containment in micronuclei, and subsequent rupture of the micronuclear envelope to histone post-translational modification aberrations. This relationship was across all tested human and murine cancer cell lines, as well as non-transformed cells. Furthermore, we discovered that the observed changes in histone PTMs were caused by either micronuclear rupture or the persistence of histone PTM status during cell division. Moreover, we revealed substantial chromatin accessibility differences in micronuclei. Notably, there is a distinct bias in chromatin accessibility between promoter regions compared to distal and intergenic regions of the genome, which aligned well with observed changes in histone modifications. The induction of chromosomal instability leads to widespread, heterogeneous, and heritable abnormalities in the epigenetic landscape of cancer cells. Therefore, on top of genomic copy number changes, chromosomal instability causes epigenetic reprogramming, which adds another layer to cancer heterogeneity. Citation Format: Albert S. Agustinus, Duaa Al-Rawi, Bhargavi Dameracharla, Ramya Raviram, Bailey S. Jones, Stephanie Stransky, Lorenzo Scipioni, Jens Luebeck, Melody Di Bona, Danguole Norkunaite, Robert M. Myers, Mercedes Duran, Seongmin Choi, Britta Weigelt, Shira Yomtoubian, Andrew McPherson, Eleonore Toufektchan, Kristina Keuper, Paul S. Mischel, Vivek Mittal, Sohrab P. Shah, John Maciejowski, Zuzana Storchova, Enrico Gratton, Peter Ly, Dan Landau, Mathieu F. Bakhoum, Richard P. Koche, Simone Sidoli, Vineet Bafna, Yael David, Samuel F. Bakhoum. Chromosomal instability causes epigenetic aberrations in cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4293.

oncology
The two sides of chromosomal instability: drivers and brakes in cancer

Rendy Hosea,Sharon Hillary,Sumera Naqvi,Shourong Wu,Vivi Kasim

DOI: https://doi.org/10.1038/s41392-024-01767-7

IF: 39.3

2024-03-30

Signal Transduction and Targeted Therapy

Abstract:Chromosomal instability (CIN) is a hallmark of cancer and is associated with tumor cell malignancy. CIN triggers a chain reaction in cells leading to chromosomal abnormalities, including deviations from the normal chromosome number or structural changes in chromosomes. CIN arises from errors in DNA replication and chromosome segregation during cell division, leading to the formation of cells with abnormal number and/or structure of chromosomes. Errors in DNA replication result from abnormal replication licensing as well as replication stress, such as double-strand breaks and stalled replication forks; meanwhile, errors in chromosome segregation stem from defects in chromosome segregation machinery, including centrosome amplification, erroneous microtubule–kinetochore attachments, spindle assembly checkpoint, or defective sister chromatids cohesion. In normal cells, CIN is deleterious and is associated with DNA damage, proteotoxic stress, metabolic alteration, cell cycle arrest, and senescence. Paradoxically, despite these negative consequences, CIN is one of the hallmarks of cancer found in over 90% of solid tumors and in blood cancers. Furthermore, CIN could endow tumors with enhanced adaptation capabilities due to increased intratumor heterogeneity, thereby facilitating adaptive resistance to therapies; however, excessive CIN could induce tumor cells death, leading to the "just-right" model for CIN in tumors. Elucidating the complex nature of CIN is crucial for understanding the dynamics of tumorigenesis and for developing effective anti-tumor treatments. This review provides an overview of causes and consequences of CIN, as well as the paradox of CIN, a phenomenon that continues to perplex researchers. Finally, this review explores the potential of CIN-based anti-tumor therapy.

biochemistry & molecular biology,cell biology
Extrachromosomal Circular DNA: A New Target in Cancer

Pan Wu,Yuhang Liu,Ruijia Zhou,Lingyun Liu,Hongli Zeng,Fang Xiong,Shanshan Zhang,Zhaojian Gong,Wenling Zhang,Can Guo,Fuyan Wang,Ming Zhou,Xuyu Zu,Zhaoyang Zeng,Yong Li,Guiyuan Li,He Huang,Wei Xiong

DOI: https://doi.org/10.3389/fonc.2022.814504

IF: 4.7

2022-04-14

Frontiers in Oncology

Abstract:Genomic instability and amplification are intrinsically important traits determining the development and heterogeneity of tumors. The role of extrachromosomal circular DNA (eccDNA) in tumors has recently been highlighted. EccDNAs are unique genetic materials located off the chromosomal DNA. They have been detected in a variety of tumors. This review analyzes the mechanisms involved in the formation of eccDNAs and their genetic characteristics. In addition, the high-copy number and transcriptional levels of oncogenes located in eccDNA molecules contribute to the acceleration of tumor evolution and drug resistance and drive the development of genetic heterogeneity. Understanding the specific genomic forms of eccDNAs and characterizing their potential functions will provide new strategies for tumor therapy. Further research may yield new targets and molecular markers for the early diagnosis and treatment of human cancer.

oncology
Pervasive chromosomal instability and karyotype order in tumour evolution

Thomas B K Watkins,Emilia L Lim,Marina Petkovic,Sergi Elizalde,Nicolai J Birkbak,Gareth A Wilson,David A Moore,Eva Grönroos,Andrew Rowan,Sally M Dewhurst,Jonas Demeulemeester,Stefan C Dentro,Stuart Horswell,Lewis Au,Kerstin Haase,Mickael Escudero,Rachel Rosenthal,Maise Al Bakir,Hang Xu,Kevin Litchfield,Wei Ting Lu,Thanos P Mourikis,Michelle Dietzen,Lavinia Spain,George D Cresswell,Dhruva Biswas,Philippe Lamy,Iver Nordentoft,Katja Harbst,Francesc Castro-Giner,Lucy R Yates,Franco Caramia,Fanny Jaulin,Cécile Vicier,Ian P M Tomlinson,Priscilla K Brastianos,Raymond J Cho,Boris C Bastian,Lars Dyrskjøt,Göran B Jönsson,Peter Savas,Sherene Loi,Peter J Campbell,Fabrice Andre,Nicholas M Luscombe,Neeltje Steeghs,Vivianne C G Tjan-Heijnen,Zoltan Szallasi,Samra Turajlic,Mariam Jamal-Hanjani,Peter Van Loo,Samuel F Bakhoum,Roland F Schwarz,Nicholas McGranahan,Charles Swanton

DOI: https://doi.org/10.1038/s41586-020-2698-6

IF: 64.8

Nature

Abstract:Chromosomal instability in cancer consists of dynamic changes to the number and structure of chromosomes1,2. The resulting diversity in somatic copy number alterations (SCNAs) may provide the variation necessary for tumour evolution1,3,4. Here we use multi-sample phasing and SCNA analysis of 1,421 samples from 394 tumours across 22 tumour types to show that continuous chromosomal instability results in pervasive SCNA heterogeneity. Parallel evolutionary events, which cause disruption in the same genes (such as BCL9, MCL1, ARNT (also known as HIF1B), TERT and MYC) within separate subclones, were present in 37% of tumours. Most recurrent losses probably occurred before whole-genome doubling, that was found as a clonal event in 49% of tumours. However, loss of heterozygosity at the human leukocyte antigen (HLA) locus and loss of chromosome 8p to a single haploid copy recurred at substantial subclonal frequencies, even in tumours with whole-genome doubling, indicating ongoing karyotype remodelling. Focal amplifications that affected chromosomes 1q21 (which encompasses BCL9, MCL1 and ARNT), 5p15.33 (TERT), 11q13.3 (CCND1), 19q12 (CCNE1) and 8q24.1 (MYC) were frequently subclonal yet appeared to be clonal within single samples. Analysis of an independent series of 1,024 metastatic samples revealed that 13 focal SCNAs were enriched in metastatic samples, including gains in chromosome 8q24.1 (encompassing MYC) in clear cell renal cell carcinoma and chromosome 11q13.3 (encompassing CCND1) in HER2+ breast cancer. Chromosomal instability may enable the continuous selection of SCNAs, which are established as ordered events that often occur in parallel, throughout tumour evolution.
DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy

Ruixue Huang,Ping-Kun Zhou

DOI: https://doi.org/10.1038/s41392-021-00648-7

IF: 39.3

2021-07-09

Signal Transduction and Targeted Therapy

Abstract:Abstract Genomic instability is the hallmark of various cancers with the increasing accumulation of DNA damage. The application of radiotherapy and chemotherapy in cancer treatment is typically based on this property of cancers. However, the adverse effects including normal tissues injury are also accompanied by the radiotherapy and chemotherapy. Targeted cancer therapy has the potential to suppress cancer cells’ DNA damage response through tailoring therapy to cancer patients lacking specific DNA damage response functions. Obviously, understanding the broader role of DNA damage repair in cancers has became a basic and attractive strategy for targeted cancer therapy, in particular, raising novel hypothesis or theory in this field on the basis of previous scientists’ findings would be important for future promising druggable emerging targets. In this review, we first illustrate the timeline steps for the understanding the roles of DNA damage repair in the promotion of cancer and cancer therapy developed, then we summarize the mechanisms regarding DNA damage repair associated with targeted cancer therapy, highlighting the specific proteins behind targeting DNA damage repair that initiate functioning abnormally duo to extrinsic harm by environmental DNA damage factors, also, the DNA damage baseline drift leads to the harmful intrinsic targeted cancer therapy. In addition, clinical therapeutic drugs for DNA damage and repair including therapeutic effects, as well as the strategy and scheme of relative clinical trials were intensive discussed. Based on this background, we suggest two hypotheses, namely “environmental gear selection” to describe DNA damage repair pathway evolution, and “DNA damage baseline drift”, which may play a magnified role in mediating repair during cancer treatment. This two new hypothesis would shed new light on targeted cancer therapy, provide a much better or more comprehensive holistic view and also promote the development of new research direction and new overcoming strategies for patients.

biochemistry & molecular biology,cell biology
[Genetic instability, a factor limiting the efficiency of targeted therapies in solid oncology]

Amandine Billaud,Louise-Marie Chevalier,Mario Campone,Alain Morel,Frédéric Bigot

DOI: https://doi.org/10.1016/j.bulcan.2020.08.010

Abstract:Genomic instability is one of the main properties of tumour development, promoting first the acquisition of genetic alterations and thus carcinogenesis. Then, the chronic and anarchic proliferation of cancer cells also supports and contributes to this instability allowing a continuous evolution of the tumour. The accumulation of mutations resulting from that instability contributes to tumour heterogeneity that occurs in a specific environment. The resulting diversity of oncogenic drivers further complicates the characterization of the origin of cancer cells dysfunction and consequently therapeutic decision. However, the consideration of the molecular context in oncology has initiated the development of targeted therapies. Based on the concept of oncogene addiction and synthetic lethality, these new drugs require the characterization and identification of specific tumour biomarkers. Targeted therapies have thus considerably optimized patient management, improving efficiency and quality of life while limiting the side effects observed with conventional chemotherapies. However, despite significant clinical benefits, some major limitations to their administration remain. The study of the current issues related to these new therapeutic molecules is becoming crucial for patient management towards an improvement of personalized medicine.
Abstract SY22-01: A strategy to intervene mitotic kinases to induce mitotic catastrophe in cancer cells

Motoko Takahashi,Minji Jo,Nana Kamakura,Chang Liu,Utako Kato,Toru Hirota

DOI: https://doi.org/10.1158/1538-7445.am2024-sy22-01

IF: 11.2

2024-04-07

Cancer Research

Abstract:Chromosomal instability (CIN) is an outstanding feature of cancer, which relates to intratumor heterogeneity, therapeutic resistance, and poor prognosis. While cancer cells can proliferate with CIN, experimentally induced aneuploidy is known to suppress cell growth, leading to the idea that extreme ploidy changes are detrimental to cancer cells. One of the major etiologies of CIN is abnormal kinetochore microtubule attachments, followed by chromosome missegregation. To avoid this, cells have evolved a robust system including two molecular networks for stabilizing and destabilizing microtubule attachments. Two mitotic kinases are involved in this system which have opposite but balanced mode of actions. We previously found that a wide range of cancer cells are defective for destabilization and results in an elevated rate of missegregation. In this study, we aimed to manipulate this kinase balance and found that weighing the balance to stabilizers can cause catastrophic chromosome segregation in mitosis, and such effect could be induced predominantly in cancer cells. These findings prompted us to undertake a screen for small molecules targeting the balanced activity of mitotic kinases. Citation Format: Motoko Takahashi, Minji Jo, Nana Kamakura, Chang Liu, Utako Kato, Toru Hirota. A strategy to intervene mitotic kinases to induce mitotic catastrophe in cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr SY22-01.

oncology
Targeting DNA damage response pathways in cancer

Florian J. Groelly,Matthew Fawkes,Rebecca A. Dagg,Andrew N. Blackford,Madalena Tarsounas

DOI: https://doi.org/10.1038/s41568-022-00535-5

IF: 78.5

2022-12-06

Nature Reviews Cancer

Abstract:Cells have evolved a complex network of biochemical pathways, collectively known as the DNA damage response (DDR), to prevent detrimental mutations from being passed on to their progeny. The DDR coordinates DNA repair with cell-cycle checkpoint activation and other global cellular responses. Genes encoding DDR factors are frequently mutated in cancer, causing genomic instability, an intrinsic feature of many tumours that underlies their ability to grow, metastasize and respond to treatments that inflict DNA damage (such as radiotherapy). One instance where we have greater insight into how genetic DDR abrogation impacts on therapy responses is in tumours with mutated BRCA1 or BRCA2 . Due to compromised homologous recombination DNA repair, these tumours rely on alternative repair mechanisms and are susceptible to chemical inhibitors of poly(ADP-ribose) polymerase (PARP), which specifically kill homologous recombination-deficient cancer cells, and have become a paradigm for targeted cancer therapy. It is now clear that many other synthetic-lethal relationships exist between DDR genes. Crucially, some of these interactions could be exploited in the clinic to target tumours that become resistant to PARP inhibition. In this Review, we discuss state-of-the-art strategies for DDR inactivation using small-molecule inhibitors and highlight those compounds currently being evaluated in the clinic.

oncology
Abstract 6630: Non-cell-autonomous cancer progression from chromosomal instability

Jun Li,Melissa Hubisz,Ethan Earlie,Mercedes Duran,Christy Hong,Austin Varela,Emanuele Lettera,Matthew Deyell,Bernardo Tavora,Jonathan Havel,Phyu Su,Amit Dipak Amin,Karolina Budre,Erina Kamiya,Julie-Ann Cavallo,Christopher Garris,Simon Powell,Jorge Reis-Filho,Hannah Wen,Sarah Bettigole,Atif Khan,Benjamin Izar,Eileen Parkes,Ashley Laughney,Samuel Bakhoum

DOI: https://doi.org/10.1158/1538-7445.am2024-6630

IF: 11.2

2024-03-31

Cancer Research

Abstract:Chromosomal instability (CIN) is a driver of cancer metastasis, yet the extent to which this effect depends on the immune system remains unknown. Using ContactTracing—a newly developed, validated and benchmarked tool to infer the nature and conditional dependence of cell-cell interactions from single-cell transcriptomic data—we show that CIN-induced chronic activation of the cGAS-STING pathway promotes downstream signal re-wiring in cancer cells, leading to a pro-metastatic tumor microenvironment. This re-wiring is manifested by type I interferon tachyphylaxis selectively downstream of STING and a corresponding increase in cancer cell-derived endoplasmic reticulum (ER) stress response. Reversal of CIN, depletion of cancer cell STING or inhibition of ER stress response signaling abrogates CIN-dependent effects on the tumor microenvironment and suppresses metastasis in immune competent, but not severely immune compromised, settings. Treatment with STING inhibitors reduces CIN-driven metastasis in melanoma, breast and colorectal cancers in a manner dependent on tumor cell-intrinsic STING. Finally, we show that CIN and pervasive cGAS activation in micronuclei are associated with ER stress signaling, immune suppression and metastasis in human triple-negative breast cancer, highlighting a viable strategy to identify and therapeutically intervene in tumors spurred by CIN-induced inflammation. Citation Format: Jun Li, Melissa Hubisz, Ethan Earlie, Mercedes Duran, Christy Hong, Austin Varela, Emanuele Lettera, Matthew Deyell, Bernardo Tavora, Jonathan Havel, Phyu Su, Amit Dipak Amin, Karolina Budre, Erina Kamiya, Julie-Ann Cavallo, Christopher Garris, Simon Powell, Jorge Reis-Filho, Hannah Wen, Sarah Bettigole, Atif Khan, Benjamin Izar, Eileen Parkes, Ashley Laughney, Samuel Bakhoum. Non-cell-autonomous cancer progression from chromosomal instability [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6630.

oncology

Targeting cancers with chromosome instability

Targeting chromosomal instability and aneuploidy in cancer

A CINful way to overcome addiction: how chromosomal instability enables cancer to overcome its oncogene addiction

Abstract IA15: Single cell origins and targeting of genomic instability in breast cancers

Targeting RNA and Protein Turnover in Aneuploid Cancers

Abstract IA010: Latest developments in targeting the DNA damage response in the clinic

Decoding the genetic program of micronucleus formation: linking chromosomal instability to human disease

The Role of Non-Coding RNAs in Chromosomal Instability in Cancer

Abstract MS1-3: Targeting DNA damage response and HRD in breast cancer

Therapeutic index of targeting select chromatin complexes in human cancer patients

Chromosomal instability as a driver of cancer progression

Chromosome instability functions as a potential therapeutic reference by enhancing chemosensitivity to BCL-XL inhibitors in colorectal carcinoma

Abstract 4293: Chromosomal instability causes epigenetic aberrations in cancer

The two sides of chromosomal instability: drivers and brakes in cancer

Extrachromosomal Circular DNA: A New Target in Cancer

Pervasive chromosomal instability and karyotype order in tumour evolution

DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy

[Genetic instability, a factor limiting the efficiency of targeted therapies in solid oncology]

Abstract SY22-01: A strategy to intervene mitotic kinases to induce mitotic catastrophe in cancer cells

Targeting DNA damage response pathways in cancer

Abstract 6630: Non-cell-autonomous cancer progression from chromosomal instability